
Opinion|Videos|March 17, 2025
Optimizing Phlebotomy and Cytoreductive Therapy in PV
Author(s)Prithviraj Bose, MD
A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line therapy in patients with polycythemia vera (PV) requiring combined phlebotomy and cytoreductive treatment, focusing on hematocrit control, symptom improvement, phlebotomy frequency reduction, and molecular marker trends as key indicators of therapeutic efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please discuss which clinical and laboratory parameters you find most valuable when assessing response to first-line therapy, particularly in patients with PV requiring both phlebotomy and cytoreductive therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
BI-1808 Plus Pembrolizumab Yield Antitumor Activity in Recurrent Ovarian Cancer
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5


















